NCT00352144View on ClinicalTrials.gov

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

PHASE3CompletedINTERVENTIONAL

Enrollment

830

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions

Primary Insomnia

Interventions

DRUG

Eszopiclone

Eszopiclone 3 mg

DRUG

Placebo

Placebo tablet

Trial Locations (58)

Unknown

Birmingham

Huntsville

Phoenix

Scottsdale

Anaheim

Irvine

Oakland

Redlands

San Diego

Aurora

Denver

Longmont

Pueblo

Clearwater

Jacksonville

Jupiter

Naples

Orlando

Pembroke Pines

Pinellas Park

St. Petersburg

Tampa

Atlanta

Blairsville

Chicago

Elk Grove Village

Northbrook

Evansville

Olathe

Prairie Village

Chevy Chase

Frederick

Newton

Kansas City

St Louis

Lincoln

Las Vegas

Hamilton

New York

Cary

Cincinnati

Cleveland

Columbus

Mogadore

Oklahoma City

Eugene

Bala-Cynwyd

Anderson

Columbia

Austin

Dallas

Houston

Jackson

Lubbock

Plano

San Antonio

Brown Deer

Madison

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00352144 - 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia | Biotech Hunter | Biotech Hunter